市場調査レポート

商品コード

1593508

細胞・遺伝子治療の市場規模・シェア・成長分析 (治療の種類別、治療クラス別、送達手段別、エンドユーザー別、地域別)：産業予測 (2024～2031年)

Cell and Gene Therapy Market Size, Share, Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic class (Cardiovascular Disease, Cancer), By Delivery Method, By End-Users, By Region - Industry Forecast 2024-2031

出版日: 2024年11月13日
発行: SkyQuest
ページ情報: 英文 194 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の細胞・遺伝子治療の市場規模は、2022年に177億米ドルと評価され、2023年の209億7,000万米ドルから2031年には815億5,000万米ドルに拡大し、予測期間中 (2024～2031年) に18.50%のCAGRで成長する見通しです。

細胞・遺伝子治療市場は、遺伝子工学の進歩や細胞研究への投資の増加により、今後数年間で大きな成長を遂げることが予想されます。さまざまな疾患に対する革新的な細胞・遺伝子治療の適用拡大が、業界関係者に新たな機会をもたらしています。高度な治療オプションに対する需要の高まりや慢性疾患の蔓延と相まって、患者ケアの強化に重点が置かれていることが、市場拡大を後押しする極めて重要な要因となっています。さらに、個別化医療への傾向や、画期的な治療法に対する規制当局の承認率の上昇が、この分野における新たなビジネス展望への道をさらに開いています。しかし、先進治療に伴う高コスト、限られた償還オプション、新規治療へのアクセス制限といった課題もあり、革新的ソリューションの幅広い採用の妨げとなる可能性があります。これらの制約に対処することは、細胞・遺伝子治療市場の潜在能力をフルに発揮させ、将来の医療の進歩にとって重要な分野と位置づけるために不可欠です。全体として、技術革新と進化する患者のニーズが組み合わさることで、細胞・遺伝子治療市場は有望な軌道に乗ることが示唆され、医療業界における投資と開発にとって魅力的な分野となっています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ (MEA)
- 湾岸協力会議 (GCC) 諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング (2023年)
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア (2023年)

主要企業プロファイル

Alnylam Pharmaceuticals Inc. (米国)
Amgen Inc. (米国)
Biogen Inc. (米国)
CORESTEM Inc. (米国)
Helixmith Co. Ltd. (韓国)
JCR Pharmaceuticals Co. Ltd. (日本)
Kolon TissueGene Inc. (韓国)
Novartis AG (スイス)
Pfizer Inc. (米国)
Gilead Sciences, Inc. (米国)
Sangamo Therapeutics, Inc. (米国)
Bluebird Bio, Inc. (米国)
Zymeworks Inc. (カナダ)
CRISPR Therapeutics AG (スイス)
Celyad Oncology SA (ベルギー)
Atara Biotherapeutics, Inc. (米国)
Athenex, Inc. (米国)
Bristol Myers Squibb (米国)
Kyowa Kirin (日本)
Sanofi (フランス)

Product Code: SQMIG35G2300

Global Cell and Gene Therapy Market size was valued at USD 17.7 billion in 2022 and is poised to grow from USD 20.97 billion in 2023 to USD 81.55 billion by 2031, growing at a CAGR of 18.50% during the forecast period (2024-2031).

The cell and gene therapy market is set to experience significant growth in the coming years, driven by advancements in genetic engineering and increased investments in cellular research. The expanding application of innovative cell and gene therapies for a range of diseases presents new opportunities for industry players. A heightened focus on enhancing patient care, coupled with the rising demand for advanced treatment options and the growing prevalence of chronic diseases, are pivotal factors propelling market expansion. Additionally, the trend towards personalized medicine and the increasing rate of regulatory approvals for groundbreaking therapies further pave the way for new business prospects within this sector. However, the market does face challenges, namely the high costs associated with advanced therapies, limited reimbursement options, and restricted access to novel treatments, which may hinder broader adoption of these innovative solutions. Addressing these constraints will be essential for realizing the full potential of the cell and gene therapy market, positioning it as a key area for future healthcare advancements. Overall, the combination of technological innovation and evolving patient needs suggests a promising trajectory for the cell and gene therapy landscape, making it an appealing area for investment and development in the healthcare industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Market Segmental Analysis

Global Cell and Gene Therapy Market is segmented by Therapy Type, Therapeutic class, Delivery Method, End-Users, and region. Based on Therapy Type, the market is segmented into Cell Therapy, Stem Cells (T Cells, Dendritic Cells, NK Cells, Tumor Cells), Gene Therapy (Gene Silencing, Cell Replacement, Gene Augmentation, Other Therapies). Based on Therapeutic class, the market is segmented into Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, and Others. Based on Delivery Method, the market is segmented into In Vivo, and Ex Vivo. Based on End-Users, the market is segmented into Hospitals, Cancer Care Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell And Gene Therapy Market

Advancements in gene technologies are a significant market driver for the Global Cell and Gene Therapy market. These innovations, including CRISPR, recombinant DNA technology, and next-generation sequencing, have enhanced the precision and efficacy of gene editing and modification, paving the way for targeted therapies. With the increasing prevalence of genetic disorders, cancer, and rare diseases, these advanced technologies facilitate the development of more personalized and effective treatment options. Furthermore, ongoing research and investment in biopharmaceuticals are accelerating the translation of these technologies from the lab to clinical applications, propelling market growth and attracting both public and private funding.

Restraints in the Global Cell And Gene Therapy Market

One of the significant market restraints for the global cell and gene therapy market is the prohibitively high costs associated with these treatments. The complex and specialized nature of developing gene and cell therapies often results in substantial research and development expenditures, which are subsequently passed on to patients. This financial barrier limits access for a considerable segment of the population, potentially leading to disparities in treatment availability. Additionally, the high price tag poses challenges for healthcare providers and payers in terms of reimbursement and health insurance coverage, ultimately hindering market growth and patient adoption of these innovative therapies.

Market Trends of the Global Cell And Gene Therapy Market

The Global Cell and Gene Therapy market is witnessing a notable trend towards the increasing demand for combination therapies, which integrate the advantages of both gene and cell therapies. This trend is driven by a growing recognition of the high efficacy these integrated approaches offer in treating complex and multifaceted medical conditions. As healthcare professionals and patients alike seek more effective treatment options, cell and gene therapy companies are urged to innovate and develop novel combination therapies. This focus aims to enhance patient outcomes across a variety of disease indications, thereby positioning companies favorably within a rapidly evolving biopharmaceutical landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition
Market Attractiveness Index, 2023

Cell and Gene Therapy Market by Therapy Type

Market Overview
Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Tumor Cells
Gene Therapy
- Gene Silencing
- Cell Replacement
- Gene Augmentation
- Other Therapies

Cell and Gene Therapy Market by Therapeutic class

Market Overview
Cardiovascular Disease
Cancer
Genetic Disorder
Rare Diseases
Oncology
Hematology
Ophthalmology
Infectious Disease
Neurological Disorders
Others

Cell and Gene Therapy Market by Delivery Method

Market Overview
In Vivo
Ex Vivo

Cell and Gene Therapy Market by End-Users

Market Overview
Hospitals
Cancer Care Centers
Others

Cell and Gene Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Alnylam Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CORESTEM Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Helixmith Co. Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JCR Pharmaceuticals Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celyad Oncology SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atara Biotherapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

細胞・遺伝子治療の市場規模・シェア・成長分析 (治療の種類別、治療クラス別、送達手段別、エンドユーザー別、地域別)：産業予測 (2024～2031年)

Cell and Gene Therapy Market Size, Share, Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic class (Cardiovascular Disease, Cancer), By Delivery Method, By End-Users, By Region - Industry Forecast 2024-2031

目次

イントロダクション

分析手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

細胞・遺伝子治療市場：治療の種類別

細胞・遺伝子治療市場：治療クラス別

細胞・遺伝子治療市場：送達手段別

細胞・遺伝子治療市場：エンドユーザー別

細胞・遺伝子治療市場：地域別